1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene

• ChemBase编号: 154
• 分子式: C23H21ClO3
• 平均质量: 380.86404
• 单一同位素质量: 380.11792221
• SMILES: Cl/C(=C(/c1ccc(OC)cc1)\c1ccc(OC)cc1)/c1ccc(OC)cc1
• Canonical SMILES: COc1ccc(cc1)/C(=C(\c1ccc(cc1)OC)/Cl)/c1ccc(cc1)OC
• InChI: InChI=1S/C23H21ClO3/c1-25-19-10-4-16(5-11-19)22(17-6-12-20(26-2)13-7-17)23(24)18-8-14-21(27-3)15-9-18/h4-15H,1-3H3
• InChIKey: BFPSDSIWYFKGBC-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 1-[1-chloro-2,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene; 1-[2-chloro-1,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene
• IUPAC传统名: chlorotrianisene; 1-[2-chloro-1,2-bis(4-methoxyphenyl)ethenyl]-4-methoxybenzene
• 商标名: Anisene; Chlorotrisin; Clorestrolo; Clorotrisin; Hormonisene; Khlortrianizen; Merbentul; Metace; Rianil; Tace; Tace-Fn; Trianisestrol
• 别名: Chlorotrianisenum [INN-Latin]; Chlorotrianisine; Chlorotrianizen; Chlortrianisen; Chlortrianisene; Chlortrianisenum; Chlortrianisestrol; Chlortrianisoestrolum; Clorotrianiseno [INN-Spanish]; CTA; Chloortrianisestrol; Chlorestrolo; Chlortrianizen; Chlorotrianisene; TACE; Chlorotrianisene

登记号

• CAS号: 569-57-3
• EC号: 209-318-6
• MDL号: MFCD00048044
• PubChem SID: 46508811; 24892934; 160963617
• PubChem CID: 11289
• CHEBI ID: 3641
• ATC码: G03CA06
• CHEMBL: 1200761
• Chemspider ID: 10815
• DrugBank ID: DB00269
• KEGG ID: D00269
• 美国药典/FDA物质标识码: 6V5034L121
• 维基百科标题: Chlorotrianisene

理论计算性质

JChem

• 质子受体: 3
• 质子供体: 0
• LogD (pH = 5.5): 5.427335
• LogD (pH = 7.4): 5.427335
• Log P: 5.427335
• 摩尔折射率: 119.1713 cm^3
• 极化性: 42.46953 Å^3
• 极化表面积: 27.69 Å^2
• 可自由旋转的化学键: 6
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 5.95
• LOG S: -6.28
• 溶解度: 1.99e-04 g/l

分子性质

理化性质

• 疏水性(logP): 6.4

安全信息

• RTECS编号: KV0600000
• 德国WGK号: 3
• 个人保护装置: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter

药理学性质

• 给药途径: Oral
• 蛋白结合率: 50 to 80%
• 法定药品分级: Discontinued
• 妊娠期药物分类: X (US)

产品相关信息

• 纯度: ~95%
• Empirical Formula (Hill Notation): C23H21ClO3

详细说明

DrugBank - DB00269

• Drug Groups: approved
• Description: A powerful synthetic, non-steroidal estrogen. [PubChem]
• Indication: Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.
• Pharmacology: Chlorotrianisene is a nonsteroidal synthetic estrogen. After menopause, when the body no longer produces estrogen, chlorotrianisene is used as a simple replacement of estrogen. The estrogen-stimulated endometrium may bleed within 48-72 hours after discontinuance of estrogen therapy. Paradoxically, prolonged estrogen therapy may cause shrinkage of the endometrium and an increase in size of the myometrium. Estrogens have a weak anabolic effect and may cause sodium retention with associated fluid retention and edema. Estrogens may also decrease elevated blood cholesterol and phospholipid concentrations. Estrogens affect bone by increasing calcium deposition and accelerating epiphyseal closure, following initial growth stimulation. During the preovulatory or nonovulatory phase of the menstrual cycle, estrogen is the principal determinant in the onset of menstruation. A decline of estrogenic activity at the end of the menstrual cycle also may induce menstruation; however, the cessation of progesterone secretion is the most important factor during the mature ovulatory phase of the menstrual cycle. The benefit derived from estrogen therapy in the prevention of postpartum breast engorgement must be carefully weighed against the potential increased risk of puerperal thromboembolism associated with the use of large doses of estrogens.
• Toxicity: Acute overdosage of large doses of oral contraceptives in chidren reportedly produces almost no toxicity except nausea and vomiting. Acute overdosage of estrogens may cause nausea, and withdrawal bleeding may occur in females.
• Affected Organisms: Humans and other mammals
• Biotransformation: Metabolized principally in the liver, although the kidneys, gonads, and muscle tissues may be involved to some extent. The metabolic fate of the synthetic estrogens has not been fully elucidated.
• Absorption: Absorption following oral administration is rapid.
• Protein Binding: 50-80%
• External Links: Wikipedia; Drugs.com

Sigma Aldrich - C7128

Biochem/physiol Actions
Non-steroidal estrogenic compound which is metabolized by liver microsomal enzymes primarily to the mono-O-demethylated derivative.1